Dr. Daniel Freitag

Bayer AG, Berlin


Daniel Freitag heads the cardiovascular data sciences group within the drug discovery function at Bayer AG. He studied molecular biomedicine at the University of Bonn, prior to obtaining a Master’s degree in Epidemiology and a PhD in human genetics at the University of Cambridge, UK. After his postdoctoral training at the Wellcome Trust Sanger Institute and the University of Cambridge, UK he joined Bayer in 2015. In his current role, he and his group support pre-clinical and early clinical drug discovery projects in cardiovascular indications through analysis of large-scale datasets, including human genomic data.

At Future Medicine 2017 he will talk about "Leveraging nature’s randomized trials for drug discovery".